Literature DB >> 15714369

Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia.

Daniel G Clair1, Rajeev Dayal, Peter L Faries, Joshua Bernheim, Roman Nowygrod, John C Lantis, Frederick P Beavers, K Craig Kent.   

Abstract

The purpose of this study was to assess the technical feasibility and early outcome of tibial angioplasty for a subset of patients with limb-threatening ischemia who were not candidates for bypass grafting. A retrospective analysis was conducted of 19 patients (7 male, 12 female) who underwent crural angioplasty for limb-threatening ischemia using 0.018- or 0.014 inch-based systems. Contraindications to bypass were insufficient conduit in 7 patients and severe comorbid illness in 12. Concurrent treatment of inflow lesions was performed in 12 of 20 limbs via either angioplasty alone (5) or combined with stenting (12). Outcome measures were ankle-brachial indices (ABI), relief of rest pain, and healing or healed wounds. Twenty-three vessels were treated, including 14 tibial occlusions and 9 stenoses. The average length of diseased segment was 11 cm (range, 3-25 cm). Thirteen of 14 occlusions were treated with subintimal recanalization, the remainder with laser recanalization. Technical success was achieved in 22 of 23 treated vessels. Mean preoperative ABI was 0.53 and mean postoperative ABI was 0.85. Palpable pulses were present in 11 of 20 limbs (55%). There was one perioperative mortality (5.2%). Mean follow-up was 3 months. Three failures occurred requiring amputation (15.8%). The remaining 16 patients were improved with healing (8) or healed (4) wounds and relief of rest pain (4). These results indicate that technical success may be achieved with outflow lesion angioplasty in the majority of patients encountered. The durability of this method of therapy is unknown, and our length of follow-up is not sufficient to answer this question. However, an attempt at angioplasty appears justified before primary amputation and before surgical bypass in those patients at high risk for intervention.

Entities:  

Mesh:

Year:  2005        PMID: 15714369     DOI: 10.1007/s10016-004-0136-0

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  6 in total

1.  Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia between patients with and without diabetes.

Authors:  Jeremy D Darling; Thomas C F Bodewes; Sarah E Deery; Raul J Guzman; Mark C Wyers; Allen D Hamdan; Hence J Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-09-22       Impact factor: 4.268

2.  Results for primary bypass versus primary angioplasty/stent for lower extremity chronic limb-threatening ischemia.

Authors:  Jeremy D Darling; John C McCallum; Peter A Soden; Lindsey Korepta; Raul J Guzman; Mark C Wyers; Allen D Hamdan; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-03-06       Impact factor: 4.268

Review 3.  Contemporary treatment for critical ischemia: the evidence for interventional radiology or surgery.

Authors:  Keith Hussey; Sivanathan Chandramohan
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

4.  Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions.

Authors:  Brian G DeRubertis; Peter L Faries; James F McKinsey; Rabih A Chaer; Matthew Pierce; John Karwowski; Alan Weinberg; Roman Nowygrod; Nicholas J Morrissey; Harry L Bush; K Craig Kent
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

5.  Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia in insulin-dependent diabetic patients.

Authors:  Jeremy D Darling; Thomas F X O'Donnell; Sarah E Deery; Anthony V Norman; Giap H Vu; Raul J Guzman; Mark C Wyers; Allen D Hamdan; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2018-11       Impact factor: 4.268

6.  Clinical outcomes of infrapopliteal angioplasty in patients with critical limb ischemia.

Authors:  Hyeon Min Ryu; Jung-Sun Kim; Young Guk Ko; Myeong-Ki Hong; Yangsoo Jang; Donghoon Choi
Journal:  Korean Circ J       Date:  2012-04-26       Impact factor: 3.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.